EUVIMEDOpdag EUVIMED
Leserbrief

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Chang-Yu Hsieh iD, Tsen-Fang Tsai iD

Experimental Dermatology · 2023

DOI: 10.1111/exd.14810 ↗

At a glance

Leserbrief in Experimental Dermatology, 2023. Written by Chang-Yu Hsieh and 1 co-authors. Institution: Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan. Major MEDLINE topics: Antibodies, Monoclonal, Psoriasis. Cited 4 times so far (Crossref); 7 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Dear Editor, The use of biologics in recent decades has revolutionized the treatment of psoriasis. However, the high cost poses a significant barrier to patients who do not have access to reimbursed biologics. Interleukin (IL)17 and IL23 blockers have become the gold standards for psoriasis treatment due to their efficacy and safety, and among them, secukinumab, an IL17A blocker, is the only biologic which can be given in reduced doses (150 mg every 4 weeks after initial loading) according to the package insert in many countries (e.g. US, Japan, Taiwan, etc.) The reduced dose of secukinumab is particularly valuable for patients with lower body weight and those who are biologic naïve.1 A realworld study demonstrated that secukinumab 150 mg (SEC150) and 300 mg (SEC300) had comparable response in Chinese patients. PASI75/90/100 responses were achieved in 100%, 97.8% and 95.7% of patients, respectively, in SEC150 group and 91.5%, 86.4% and 79.9%, respectively, in SEC300 group at week 24.2 Although patients who failed secukinumab may benefit from switching to other biologics,3 the next treatment option with similar pharmacoeconomic consideration is unknown for those who used SEC150. Risankizumab is an IL23 blocker which has also been studied in reduced doses. In the SustaIMM study, PASI75/90 responses were also comparable between patients receiving 75 mg (RZB75, PASI75/90 = 90/76%) and 150 mg (RZB150, PASI75/90 = 95/75%) risankizumab in Japanese population.4 Thus, RZB75 every 12 weeks is also approved for psoriasis treatment in Japan. In the aIMM study, most patients with psoriasis who failed SEC300 or ixekizumab had improvement after switching to RZB150.5 In the IMMerge study, RZB150 showed consistently greater efficacy compared with SEC300.6 Here, we report our experience of selfpaid patients who were switched from SEC150 to RZB75 in realworld practice. We retrospectively included seven Taiwanese patients who had received secukinumab prior to risankizumab at the recommended frequencies but under reduced doses. Six females and one male with mean weight of 58.9 ± 7.2 kg and mean age (in year) of 47.6 ± 18.5 (mean ± standard deviation) were included. Four patients (patients A, C, D and G) were biologic naïve, whereas others had used various biologics before the use of secukinumab, including etanercept (N = 1), adalimumab (N = 2) and ustekinumab (N = 2). All patients had static Physicians Global Assessment (sPGA) 2– 3 and mean PASI of 6.6 ± 4.4 (mean ± standard deviation) before the initiation of SEC150. Figure 1 illustrates the change of PASI score throughout the treatment course. The duration of SEC150 use before biologic switch varied from 16 weeks to 4 years. The reasons for switch were mainly due to inadequate responses (patient C) or secondary failure (patient A, B, D, E, F and G) of SEC150. Secondary failure is defined as loss of effectiveness, that is, an increase of PASI score after a minimum of 16week treatment. Six patients were switched to RZB75 from SEC150 without interruption. One patient (patient D) who stopped SEC150 at week 28 due to financial concern resumed RZB75 one year afterwards had improvement of PASI from 4.1 to 3.4 at week 40 of risankizumab. Among the five patients (patients A, B, E, F and G) who used SEC150 for more than 52 weeks, three of them achieved PASI75 and one of them achieved PASI100 response at week 52. Nonetheless, secondary failure was observed in all of them. Thus, SEC150 was replaced with RZB75 and all five patients had decreased PASI after drug switch. All seven patients are still receiving RZB75 currently and six of them have been followed up for more than 52 weeks. Among them, two achieved PASI100 and three achieved PASI90 response at week 52. No patient discontinued risankizumab due to adverse effect. According to aIMM study, 16 weeks after biologic switch to RZB150, 63.9% and 32.1% patients achieved PASI ≤3 or ≤1, respectively.5 Our study supports the above aIMM study findings that patients with inadequate response to SEC150 may benefit from switch to RZB75, both in reduced doses. Six out of 7 (85.7%) and one out of 7 (14.2%) achieved PASI ≤3 or ≤1, respectively, at week 16. Body weight has been reported to affect the efficacy of biologics in psoriasis. In previous studies, Asian patients were 15– 20 kg lighter than Caucasians, and this might contribute to the usefulness of dose reduction for both secukinumab and risankizumab in our patients.7 In conclusion, for those who had inadequate responses to SEC150, updosing to SEC300 may be considered, which is more commonly used in clinical practice. However, switching to RZB75 appeared to provide a costeffective option. Further larger randomized

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalPsoriasisHumansAntibodies, Monoclonal, HumanizedTreatment OutcomeSeverity of Illness IndexRetrospective Studies

Author keywords

biologicspsoriasisreal-worldreduced-dosesecukinumab

Substances

risankizumabsecukinumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan.

ORCID profiles: Chang-Yu Hsieh, Tsen-Fang Tsai

Cite

APA

Hsieh, C. Y., & Tsai, T. F. (2023). Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series. Experimental Dermatology. https://doi.org/10.1111/exd.14810

Vancouver

Hsieh CY, Tsai TF. Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series. Experimental Dermatology. 2023. doi:10.1111/exd.14810

BibTeX
@article{Hsieh2023,
  author = {Hsieh, Chang-Yu and Tsai, Tsen-Fang},
  title = {Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14810}
}
Start for free →